Characterization of pneumococcal meningitis before and after introduction of 13-valent pneumococcal conjugate vaccine in Niger, 2010–2018
- 21 April 2020
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 38 (23), 3922-3929
- https://doi.org/10.1016/j.vaccine.2020.04.009
Abstract
No abstract availableFunding Information
- Gavi
- CDC (971-17)
This publication has 32 references indexed in Scilit:
- Emergence of epidemic Neisseria meningitidis serogroup C in Niger, 2015: an analysis of national surveillance dataThe Lancet Infectious Diseases, 2016
- Meningococcal Meningitis Surveillance in the African Meningitis Belt, 2004–2013Clinical Infectious Diseases, 2015
- Determination of Pneumococcal Serotypes in Meningitis Cases in Niger, 2003–2011PLOS ONE, 2013
- Pneumococci in the African Meningitis Belt: Meningitis Incidence and Carriage Prevalence in Children and AdultsPLOS ONE, 2012
- African meningitis belt pneumococcal disease epidemiology indicates a need for an effective serotype 1 containing vaccine, including for older children and adultsBMC Infectious Diseases, 2010
- Meningococcal carriage in the African meningitis beltThe Lancet Infectious Diseases, 2007
- Meningitis epidemics in Africa: A brief overviewVaccine, 2007
- Case-fatality ratio of bacterial meningitis in the African meningitis belt: We can do betterVaccine, 2007
- An Outbreak of Serotype 1Streptococcus pneumoniaeMeningitis in Northern Ghana with Features That Are Characteristic ofNeisseria meningitidisMeningitis EpidemicsThe Journal of Infectious Diseases, 2005
- Where is the meningitis belt? Defining an area at risk of epidemic meningitis in AfricaTransactions of the Royal Society of Tropical Medicine and Hygiene, 2002